drugset

drugset / Trial / NCT03745885

A Study of the Efficacy and Safety of Supaglutide in Healthy Participants

NCT03745885 ↗

Phase 1 Completed 48 enrolled Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug Supaglutide proposed dosing once (or twice) weekly in Chinese healthy subjects.

Timeline

Start: 2018-12-04
Primary completion: 2019-06-10
Completion: 2019-12-13

Publications

Lou YR, Xu YL, Xiong Y, Deng C, Wang Q. Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes. Clin Pharmacokinet. 2025 Apr;64(4):533-552. doi: 10.1007/s40262-025-01475-7. Epub 2025 Feb 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Supaglutide	Unknown	0.15 mg	Subcutaneous
Subject	Supaglutide	Unknown	0.375 mg	Subcutaneous
Subject	Supaglutide	Unknown	0.75 mg	Subcutaneous
Subject	Supaglutide	Unknown	1.5 mg	Subcutaneous
Subject	Supaglutide	Unknown	3 mg	Subcutaneous

Indications